Eculizumab for Thrombotic Microangiopathy Associated with Antibody-Mediated Rejection after ABO-Incompatible Kidney Transplantation

Figure 3

(a) Kidney allograft biopsy at postoperative day 12 in patient 2: thrombotic microangiopathy lesions, antibody-mediated rejection (t0, i0, g3, and cpt2). (b) Kidney allograft biopsy at postoperative day 54 in patient 2. Lesions of mixed acute cellular and antibody-mediates rejection (i2 i2 ti2 g2 cpt2), IF/TA 1, and no more lesions of thrombotic microangiopathy.

(a)

(b)